NDA 206056 · B Braun Medical
Piperacillin and Tazobactam and Sodium Chloride In Duplex Container
Piperacillin Sodium, Tazobactam Sodium · Intravenous
Last checked: Nov 20, 2026Latest source record: Apr 3, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2025
Apr 3, 2025
Approved uses
1
Original approval plus efficacy supplements
Registered trials
136
40 Phase 3, 20 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect May 8, 2026.
Piperacillin and Tazobactam for Injection and Sodium Chloride Injection, is a combination of piperacillin, a penicillin-class antibacterial and tazobactam, a beta-lactamase inhibitor, indicated for the treatment of: Intra-abdominal infections in adult and pediatric patients 2 months of age and older ( 1.1 ) Nosocomial pneumonia in adult and pediatric patients 2 months of age and older ( 1.2 ) Skin and skin structure infections in adults ( 1.3 ) Female pelvic infections in adults ( 1.4 ) Community-acquired pneumonia in adults ( 1.5 ) Usage to Reduce Development of Drug-Resistant Bacteria To reduce the development of drug-resistant bacteria and maintain the effectiveness of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection and other antibacterial drugs, Piperacillin and Tazobactam for Injection and Sodium Chloride Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.6 ) 1.1 Intra-abdominal Infections Piperacillin and Tazobactam for Injection and Sodium Chloride Injection is indicated in adults and pediatric patients (2 months of age and older) for the treatment of appendicitis (complicated by rupture or abscess) and peritonitis caused by beta-lactamase producing isolates of Escherichia coli or the following members of the Bacteroides fragilis group: B. fragilis, B. ovatus, B. thetaiotaomicron, or B. vulgatus . 1.2 Nosocomial Pneumonia Piperacillin and Tazobactam for Injection and Sodium Chloride Injection is indicated in adults and pediatric patients (2 months of age and older) for the treatment of nosocomial pneumonia (moderate to severe) caused by beta-lactamase producing isolates of Staphylococcus aureus and by piperacillin and tazobactam-susceptible Acinetobacter...
Mechanism: Piperacillin and Tazobactam for Injection and Sodium Chloride Injection is an antibacterial drug [see Microbiology (12.4) ].
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
3 products under this application
- PIPERACILLIN AND TAZOBACTAM AND SODIUM CHLORIDE IN DUPLEX CONTAINER · PIPERACILLIN SODIUM EQ 3GM BASE/VIAL; TAZOBACTAM SODIUM EQ 375MG BASE/VIAL · POWDER, INTRAVENOUS · Prescription
- PIPERACILLIN AND TAZOBACTAM AND SODIUM CHLORIDE IN DUPLEX CONTAINER · PIPERACILLIN SODIUM EQ 4GM BASE/VIAL; TAZOBACTAM SODIUM EQ 500MG BASE/VIAL · POWDER, INTRAVENOUS · Prescription
- PIPERACILLIN AND TAZOBACTAM AND SODIUM CHLORIDE IN DUPLEX CONTAINER · PIPERACILLIN SODIUM EQ 2GM BASE/VIAL; TAZOBACTAM SODIUM EQ 250MG BASE/VIAL · POWDER, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Piperacillin" as an intervention, any sponsor and status, largest first.
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaPivotal-lookingRecruiting
UMC UtrechtAcademic, hospital or other
NCT02735707 · 20,000 participants (planned) · Start Apr 11, 2016 · Primary completion Jun 2028
Drug: Ceftriaxone + Macrolide; Moxifloxacin or Levofloxacin and 47 more · For: Respiratory Tract Diseases; Influenza (Pandemic); Influenza and 7 more
Sites: Jacksonville, Florida; Augusta, Georgia; Chicago, Illinois · 408 sites in all
- Empirical Meropenem Versus Piperacillin/Tazobactam for Adult Patients With SepsisPivotal-lookingRecruiting
Scandinavian Critical Care Trials GroupAcademic, hospital or other
NCT06184659 · 5,800 participants (planned) · Start Jun 26, 2025 · Primary completion Jun 30, 2028
Drug: Meropenem; Piperacillin/Tazobactam · For: Sepsis; Septic Shock
Sites: Copenhagen, Denmark · 2 sites in all
- Per Oral Versus Intravenous Postoperative Antibiotics After Surgery for Complicated Appendicitis.Pivotal-lookingCompleted
Zealand University HospitalAcademic, hospital or other
NCT04803422 · 3,193 participants · Start Apr 1, 2021 · Primary completion May 31, 2024
Drug: Antibiotic · For: Complicated Appendicitis
Sites: Slagelse, Denmark · 2 sites in all
- Effect of Antibiotic Choice On ReNal Outcomes (ACORN)Pivotal-lookingCompleted
Vanderbilt University Medical CenterAcademic, hospital or other
NCT05094154 · 2,634 participants · Start Nov 10, 2021 · Primary completion Oct 21, 2022
Drug: anti-pseudomonal cephalosporin; anti-pseudomonal penicillin · For: Sepsis; AKI; Neurotoxicity
Sites: Nashville, Tennessee
- Antimicrobial Prophylaxis in Thyroid and Parathyroid SurgeryPivotal-lookingCompleted
Ito HospitalAcademic, hospital or other
NCT01805856 · 2,164 participants · Start Nov 2010 · Primary completion May 2012
Drug: PIPC piperacillin sodium; CEZ, cefazolin sodium · For: Thyroid Disease; Parathyroid Disease
Sites: Tokyo, Japan
- Piperacillin Sodium and Sulbactam Sodium for Injection (2:1) for Treatment of Respiratory and Urinary Tract InfectionStatus unknown
Xiangbei Welman Pharmaceutical Co., LtdIndustry
NCT01897831 · 2,000 participants (planned) · Start Aug 2011 · Primary completion Aug 2015
Drug: xin te mie · For: Respiratory Tract Infections; Urinary Tract Infections
Xiangbei Welman Pharmaceutical Co., LtdIndustry
NCT01760109 · 2,000 participants · Start Jul 2011 · Primary completion Jun 2016
Drug: Piperacillin Sodium and Sulbactam Sodium · For: Respiratory Tract Infections; Urinary Tract Infections
Sites: Chongqing, China
- Aminoglycosides in Early SepsisPivotal-lookingRecruiting
University Hospital, AkershusAcademic, hospital or other
NCT06712641 · 1,900 participants (planned) · Start Apr 23, 2026 · Primary completion Jun 2028
Drug: Gentamicin + narrow spectrum betalactam; Cefotaxime and 1 more · For: Sepsis
Sites: Bergen, Norway; Oslo, Norway; Trondheim, Norway · 15 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial.
Harris PNA, Tambyah PA, Lye DC, et al. · JAMA 2018 · Comparative Study, Equivalence Trial
- Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis: The BLING III Randomized Clinical Trial.
Dulhunty JM, Brett SJ, De Waele JJ, et al. · JAMA 2024 · Comparative Study, Multicenter Study
- Effect of Cefepime/Enmetazobactam vs Piperacillin/Tazobactam on Clinical Cure and Microbiological Eradication in Patients With Complicated Urinary Tract Infection or Acute Pyelonephritis: A Randomized Clinical Trial.
Kaye KS, Belley A, Barth P, et al. · JAMA 2022 · Clinical Trial, Phase III, Comparative Study
- Risk factors for vancomycin-associated acute kidney injury: A systematic review and meta-analysis.
Kim JY, Yee J, Yoon HY, et al. · Br J Clin Pharmacol 2022 · Meta-Analysis, Systematic Review
- Fosfomycin for Injection (ZTI-01) Versus Piperacillin-tazobactam for the Treatment of Complicated Urinary Tract Infection Including Acute Pyelonephritis: ZEUS, A Phase 2/3 Randomized Trial.
Kaye KS, Rice LB, Dane AL, et al. · Clin Infect Dis 2019 · Clinical Trial, Phase II, Clinical Trial, Phase III
- Empiric antibiotic regimens in adults with non-ventilator-associated hospital-acquired pneumonia: a systematic review and network meta-analysis of randomized controlled trials.
Ghadimi M, Siemieniuk RAC, Guyatt G, et al. · Clin Microbiol Infect 2024 · Systematic Review, Network Meta-Analysis
Sponsor: B Braun Medical
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.